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Background: The aim of this study was to evaluate the level of reactive oxygen metabolites (ROMs) after
chemotherapy in patients with non-small cell lung cancer (NSCLC) and its association with response to treatment.
Methods: Fifty-eight untreated NSCLC patients and twenty-three healthy subjects were selected for the study. Patients
received two courses of platinum-based chemotherapy and were evaluated for oxidative stress and treatment response.
As a marker of reactive oxygen species, ROMs levels were measured using the d-ROMs test.
Results: ROMs level (mean ± standard deviation) before chemotherapy in NSCLC patients (416 ± 135 U.CARR) was
significantly elevated (p = 0.016) compared to normal healthy subjects (320 ± 59 U.CARR). Patients who responded to
chemotherapy showed significantly decreased (p = 0.014) ROMs levels after chemotherapy, whereas patients who had
stable disease or progressive disease showed no change in ROMs level (p = 0.387).
Conclusions: NSCLC patients had significantly elevated ROMs levels before chemotherapy compared with normal
healthy subjects. Chemotherapy may suppress ROMs production in responders but not in non-responders. ROMs level
may be a predictor of clinical outcome in patients receiving chemotherapy for NSCLC.
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Several mechanisms leading to increased oxidative stress
in cancer patients have been proposed. Oxidative stress
results in accumulation of reactive oxygen species (ROS)
and reactive nitrogen species (RNS) such as hydroxyl
radicals (OH−), superoxide anion radicals (O2
−), lipid
peroxyl radicals (LOO−), and nitrite radicals (NO−)
[1-3]. Many anticancer drugs are also known to cause
peroxidative damage to lipids and other biomolecules
due to generation of free radicals [4-7]. The high level of
oxidative stress generated during chemotherapy may
overcome the antioxidant defenses of cancer cells, and
affect anti-neoplastic activity [8]. Thus the antioxidant
status of cancer patients may play an important role in
their response to chemotherapy.
Direct measurement of ROS and free radicals in a
standard laboratory is difficult owing to their biochemical* Correspondence: t-kawashima@sakura.med.toho-u.ac.jp
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article, unless otherwise stated.instability. Recently, a method of measuring reactive oxy-
gen metabolites (ROMs) in blood has been developed.
This method is the d-ROMs (derivatives of reactive oxy-
gen metabolites) test, which uses the Free Radical Analyt-
ical System (FRAS, Diacron, Grosseto, Italy) [9,10]. The
main component of ROMs is hydroperoxide. Despite the
moderate oxidative power, serum levels of hydroperoxides
can be detected because of its relative stability compared
with other parent free radicals.
The aim of this study is to evaluate the relationship
between serum ROMs level and clinical response to
chemotherapy in patients with non-small cell lung can-
cer (NSCLC).Methods
Patients and controls
Fifty-eight NSCLC patients (aged 45–86 years; 43 men,
15 women), admitted to Toho University Medical Center
Sakura Hospital between April 2007 and June 2010, were
consecutively recruited for this study. All patients hadentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Characteristics of 58 patients with non-small cell
lung cancer enrolled in the study
Characteristic Number ROMs level (U.CARR) p
Gender
Male 43 437 ± 144
Female 15 356 ± 81 0.134
Histology
Adenocarcinoma 50 395 ± 107
Squamous cell carcinoma 8 549 ± 209 0.032*
Performance status
0 41 419 ± 149
1 17 410 ± 96 0.139
Clinical stage
IIIB 21 405 ± 110
IV 37 423 ± 148 0.407
Smoking history
Current/former smoker 45 439 ± 143
Non-smoker 13 340 ± 55 0.040*
ROMs levels are expressed as mean ± SD. Mean values were compared by
unpaired-t test. *: p < 0.05. ROMs, reactive oxygen metabolites; U.CARR,
Carratelli Units.
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ical stage IIIB or IV at the time of diagnosis, and judged
to be inoperable. Staging was based on the 6th tumor
node metastasis (TNM) staging system [11]. Patients
with Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) between 2 and 4 were excluded
from the study. We also investigated 23 age-, sex- and
smoking habit-matched healthy control volunteers (aged
47–81 years; 15 men, 8 women) who visited our hospital
for health checkup between April 2007 and June 2010.
None of the patients and healthy control volunteers had
received antioxidant agents such as high-dose vitamin
supplementation.
This study was approved by the Institutional Review
Board of our institution, and written informed consent
was obtained from all patients and control subjects.
Measurement of reactive oxygen metabolites
Oxidative status was evaluated by measuring hydroper-
oxides in the serum using d-ROMs test. The test was
performed using the Free Radical Analytical System 4
(FRAS 4; Wismerll Co. Ltd. Tokyo, Japan). The test is
based on the concept that the amount of organic hydro-
peroxides present in serum is related to the free radicals
from which they are formed. When the serum sample is
dissolved in an acidic buffer, the hydroperoxides react
with the transition metal ions liberated from the pro-
teins in the acidic medium and are converted to alkoxy
and peroxy radicals. These newly formed radicals oxidize
the chromogen (N, N-diethyl-para-phenylendiamine) to
produce a colored derivative. The concentration of this
stable species can be determined by spectrophotometric
procedures (absorption at 505 nm). The normal range is
between 250 and 300 U.CARR. (Carratelli Units), where
1 U.CARR. corresponds to 0.8 mg/L H2O2. Values
higher than 300 U. CARR suggest increased oxidative
stress.
In all subjects, blood was collected from a peripheral
vein. Twenty μl of blood sample and 1 mL of buffered
solution (R2 reagent of the kit, pH 4.8) were gently
mixed in a cuvette, and then 10 μl of chromogenic sub-
strate (R1 reagent of the kit) was added into the cuvette.
After mixing, the cuvette was centrifuged for 60 seconds
at 37°C and incubated immediately in the thermostatic
block of the analyzer for 5 min at 37°C. Then, absorb-
ance at 505 nm was measured [9,10].
Chemotherapy and evaluation of clinical response to
treatment
The patients received one of the following three chemother-
apy regimens: carboplatin/paclitaxel, carboplatin/gemcita-
bine, and cisplatin/gemcitabine. The carboplatin/paclitaxel
regimen consisted of carboplatin at an area under the curve
(AUC) of 5 mg/mL • min on day 1 and paclitaxel at180 mg/m2 on day 1 every 4 weeks. The carboplatin
and gemcitabine combination consisted of carboplatin
AUC 5 mg/mL • min on day 1 plus gemcitabine
1000 mg/m2 on days 1 and 8 every 4 weeks. Carbo-
platin was replaced by cisplatin (80 mg/m2 on day 1)
in the cisplatin/gemcitabine regimen. All patients re-
ceived at least two courses of the respective regimens.
Tumor response was evaluated according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST)
[12], before chemotherapy and after two courses (8 weeks).
ROMs levels in all patients were assessed before treatment
(day 0). In 18 of 58 NSCLC patients, both tumor response
and ROMs level were evaluated after receiving the second
course of chemotherapy.
Statistical analysis
The results are expressed as mean ± standard deviation
(SD) unless stated otherwise. Levels of oxidative stress be-
tween two different groups were compared using t -tests,
as the data were normally distributed. P less than 0.05 was
considered to be statistically significant. All the above-
mentioned analyses were performed using the SPSS II
11.0 for Windows software package (SPSS Japan Inc.,
Tokyo, Japan).
Results
Baseline patient characteristics and control subjects
Patient characteristics are summarized in Tables 1 and 2.
The patient group consisted of 43 (74.1%) men and 15
women (25.9%), with a median age of 69.3 years (range,
Table 2 Demographic data and ROMs levels (U.CARR) of
non-small cell lung cancer patients before treatment and
matched controls




(Histology: Adeno/ Squ =50/ 8)
Gender (male/female) 43/15 15/8
Age (years) 69.3 ± 10.4 65.6 ± 9.5
ROMs level (U.CARR) 416 ± 135 320 ± 59.0*
Age and ROMs level are expressed as mean ± SD. Mean values were compared
by unpaired-t test.
*: p < 0.05 vs NSCLC patients. ROMs, reactive oxygen metabolites; U.CARR,

















Figure 1 ROMs levels (U. CARR) in control subjects and in
patients with non-small cell lung cancer before treatment. Data
are expressed as mean ± SD. ROMs level was elevated significantly
in patients before treatment compared with the control subjects
(p = 0.016, unpaired t-test).
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and 8 patients (13.8%) had squamous cell carcinoma. All
patients had ECOG PS of 0 or 1, and had undergone no
prior therapy. Forty-five patients (77.6%) were current or
former smokers and 13 (22.4%) patients had never smoked
(non-smokers). The ROMs levels measured by the d-ROMs
test were significantly increased in squamous cell carcinoma
patients (p = 0.032) and current/former smokers (p = 0.040)
compared with adenocarcinoma patients and non-smokers,
respectively. There were no significant differences in ROMs
level between males and females, performance status 0 and
1, and clinical stages IIIB and IV.
The control subjects consisted of 15 men (65.2%) and
8 women (34.8%), with a median age of 65.6 years
(range, 47–81 years). Eighteen control subjects (78.2%)
were current or former smokers and 5 control subjects
(21.8%) had never smoked. There were no significant
differences in age, gender ratio, and smoking habit be-
tween NSCLC patients and healthy controls. The ROMs
level (mean ± SD) in NSCLC patients before treatment
(416 ± 135 U. CARR) was elevated significantly (p = 0.016)
compared with healthy controls (320 ± 59 U. CARR)
(Table 2 and Figure 1).ROMs levels and response to chemotherapy
In 18 patients evaluated after receiving the second course
of chemotherapy, 7 patients (adenocarcinoma/squamous
cell carcinoma; 5/2) were classified as responders (complete
or partial response: CR/PR), while 11 patients (adenocar-
cinoma/squamous cell carcinoma; 9/2) were classified as
non-responders (stable disease or progressive disease: SD/
PD). Before chemotherapy, ROMs levels did not differ sig-
nificantly between responders and non-responders (491 ±
116 vs. 471 ± 63 U. CARR; p = 0.14) (Figure 2). After the
second course of chemotherapy, a significant decrease in
ROMs level was observed in responders (CR/PR) (491 ±
116 vs. 391 ± 71 U. CARR, p = 0.014) (Figure 3a), while
no change in ROMs level was found in non-responders
(SD/PD) (471 ± 63 vs. 452 ± 60 U. CARR; p = 0.387)
(Figure 3b).Follow up after the second course of chemotherapy
Eleven non-responders discontinued the chemotherapy regi-
mens after the second course. Among seven responders
(PR/CR), two patients discontinued chemotherapy after the
second course; one achieved down-staging and underwent
surgical operation, and the other developed drug-induced
interstitial pneumonia and died. One patient underwent
three courses of chemotherapy. This patient deteriorated to
PD after the third course, and ROMs level increased from
328 to 358 U.CARR. Treatment was changed to oral gefi-
tinib because of abnormal epidermal growth factor receptor
level. After chemotherapy was restarted, her condition im-
proved to PR, and ROMs level also decreased from 358 to
268 U.CARR. The remaining four patients were able to
complete four or more courses of chemotherapy and main-
tained PR/CR. In one of these four patients, ROMs level
was evaluated after the fourth course. Although ROMs level
increased from 283 to 318 U.CARR after the second course
of chemotherapy, the level decreased to 241U.CARR after
the fourth course.
Other tumor markers
In addition to ROMs levels, we measured carcinoembryo-
nic antigen (CEA) levels in patients with adenocarcinoma


















Figure 2 Pretreatment ROMs levels (U. CARR) in patients with
non-small cell lung cancer classified as responders (complete
response/partial response) and non-responders (stable disease/
progressive disease). Data are expressed as means ± SD. No
significant difference in ROMs level was observed between
responders and non-responders (p = 0.14, unpaired t-test).
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monitoring chemotherapy for NSCLC. Among seven re-
sponders, five had adenocarcinoma and two had squa-
mous cell carcinoma. Three out of five patients with
adenocarcinoma had elevated CEA levels before chemo-
therapy, and the level decreased in one and increased in
two patients after the second course of chemotherapy.
The other two patients with normal CEA levels before
chemotherapy showed changes within the normal range
even after the second course of chemotherapy. SCC levels
were elevated before chemotherapy in both patientswith
squamous cell carcinoma, and the level decreased in one
patient and increased in the other after the second course
of chemotherapy.Discussion
The main findings in our study are that: (1) ROMs level was
significantly elevated in NSCLC patients before chemother-
apy compared with age-, sex- and smoking habit-matched
healthy controls; and (2) ROMs level decreased significantly
in responders but was unchanged in non-responders after
the second course of chemotherapy.Recently, the concept of ‘persistent oxidative stress
in cancer’ has been hypothesized to partly explain the
characteristics of tumor biology such as activated tran-
scription factors and proto-oncogenes, genomic in-
stability, chemotherapy-resistance, as well as invasion
and metastasis [13]. What kinds of cells produce ROS
in cancer patients? Mounting evidence suggests that
malignant cells produce a large amount of hydrogen
peroxide [14]. Toyokuni et al. [13] reported that cancer
cells themselves produce ROS in human renal cell car-
cinoma. This mechanism is supported by previous re-
ports that a large amount of hydrogen peroxide is
produced in vitro without exogenous stimulation in
several human carcinoma cell lines, and that the anti-
oxidant system is suppressed in cancer cells [15,16].
Inokuma et al. [17] reported that serum ROS level was
elevated in proportion to tumor invasion and corre-
lated positively with tumor size, and they suggested
that one possible therapeutic strategy would be to in-
crease ROS scavenging against target ROS-triggered
signal transduction. In our study, ROMs level was sig-
nificantly elevated in NSCLC patients compared with
healthy controls, and the level decreased in responsive
NSCLC patients, but was not changed in non-responsive
patients after the second course of chemotherapy. These
changes in ROMs level may support the findings of the
above studies.
In NSCLC patients, the ROMs levels were significantly
higher in patients with squamous cell carcinoma and in
current or former smokers compared with adenocarcin-
oma (p = 0.032) and non-smokers, respectively (p = 0.040).
In the present study, all patients with squamous cell car-
cinoma were smokers, while 13 out of 50 patients with
adenocarcinoma were non-smokers. ROMs levels have
been reported to increase in smoking, diabetes and dialysis
[18]. Our findings are consistent with this report.
Indeed, accumulating evidence suggests that evalu-
ation of oxidative stress in NSCLC patients may predict
the prognosis of the patients [19]. On the other hand,
there is also a question on which markers best indicate
the general condition of oxidative stress. In this study,
we measured ROMs to evaluate the status of oxidative
stress. Several methods may be used to evaluate oxida-
tive stress, including (1) measurement of active oxygen
species, (2) detection of oxidized DNA and lipids, and
(3) quantification of antioxidants. However, the actual
measurement and evaluation of these compounds in-
volve various problems, because a large number of sub-
stances are involved in the oxidation-reduction system.
Moreover, these substances interact in a complex man-
ner through cross-talk. Therefore, interpretation of the
results requires consideration of the type of sample,
sampling site, substance measured, and method of






































After 2nd course of  
chemotherapy
P=0.387 (n=11)
Figure 3 ROMs levels (U. CARR) before and after 2nd course of chemotherapy in patients with non-small cell lung cancer classified as
responders (complete response/partial response) and non-responders (stable disease/progressive disease). Individual paired data and
mean ± SD are shown. a) A significant decrease in ROMs level is observed in responders (p = 0.014, paired t-test). b) No significant difference in
ROMs levels is found in nonresponders (p = 0.387, paired t-test).
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substances and the difference from background level is
often very small. Instead of directly measuring ROS or
free radicals, it is now possible to measure the hydro-
peroxide concentration in the blood produced by ac-
tive oxygen or free radicals, using a colorimetric method.
The measured concentration is considered to be directly
proportional to the quantity of ROMs produced by active
ROS and free radicals. Recent reports suggest that ROMs
in serum is a reliable biomarker, and that the concen-
tration of ROS in serum has a high positive correlation
with serum ROMs levels measured by the d-ROMs
test [20-23].
Oxidative stress causes injury to cells, induces gene
mutation, and is involved in carcinogenesis by influen-
cing intracellular signal transduction and transcription
factors directly or indirectly via oxidants. Easy and ac-
curate methods of measuring oxidative stress in the human
body are indispensable for investigating the association with
disease and for applying the results of research to clinical
practice. Therefore, measuring serum ROMs levels may
allow quantitative evaluation of the status of oxidative
stress in NSCLC patients and the effect of chemotherapy.
This study had a relatively small sample size and evaluated
the effect after a short course of chemotherapy. We have
been very cautious in interpreting our results. Nevertheless,our results suggest that ROMs level may be a predictor of
clinical outcome in patients receiving chemotherapy for
NSCLC. Further research on a larger number of patients is
needed to validate the present finding.
Conclusions
This report is the first to demonstrate an association be-
tween ROMs level and response to chemotherapy in pa-
tients with NSCLC. We found that in NSCLC patients,
ROMs level before chemotherapy was significantly ele-
vated compared with normal healthy subjects, and
chemotherapy might suppress ROMs production in re-
sponders but not in non-responders. ROMs may be a
predictor of clinical outcome in NSCLC patients re-
ceiving chemotherapy.
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